Clincosm LogoSign in Get a demo

GR Defect in Sputum Cells in COPD

Sponsor
Imperial College London (Other)
Overall Status
Terminated
CT.gov ID
NCT00159276
Collaborator
AstraZeneca (Industry)
1
Location
36
Duration (Months)

Study Details

Study Description

Brief Summary

To investigate a possible mechanism of the GR defect in patients with severe COPD by studying the effect of dexamethasone (Dex) on GR-GRE binding, expression of inflammatory and anti-inflammatory factors such as IL-6, IL-8, MKP-1, GILZ, SLPI production in sputum cells

Condition or Disease Intervention/Treatment Phase
  • Procedure: Induced Sputum

Study Design

Study Type:
Observational
Official Title:
GR Defect in Sputum Cells in COPD
Study Start Date :
Dec 1, 2005
Actual Primary Completion Date :
Dec 1, 2008
Actual Study Completion Date :
Dec 1, 2008

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    35 Years to 85 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    • Patients with moderate (stage II, GOLD) COPD or subjects who are healthy smokers or subjects who are non-smokers.

    • Written informed consent

    Exclusion Criteria:

    • Current upper respiratory tract infections

    • Any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study

    • Subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital London United Kingdom SW3 6LY

    Sponsors and Collaborators

    • Imperial College London
    • AstraZeneca

    Investigators

    • Principal Investigator: Sergei A Kharitonov, MD PhD, Imperial College London

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Imperial College London
    ClinicalTrials.gov Identifier:
    NCT00159276
    Other Study ID Numbers:
    • D5899N00007A
    First Posted:
    Sep 12, 2005
    Last Update Posted:
    Apr 16, 2019
    Last Verified:
    Apr 1, 2019
    Additional relevant MeSH terms:
    Lung Diseases, Obstructive
    Pulmonary Disease, Chronic Obstructive

    Study Results

    No Results Posted as of Apr 16, 2019